ASCO Guideline Updates
Here are two guidelines updates recently published:
- Antiemetics Guideline Update
Dosing information now includes the option of a 5-mg dose of olanzapine in adults and intravenous formulations of aprepitant and netupitant-palonosetron. The option of fosaprepitant is added to pediatric recommendations. Slides, a recommendations table, patient information, Emetic Risk Charts, a dosing tool, a pocket card, and visual abstracts on breakthrough medications, emetic risk potential, and Olanzapine iCPi are available.
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers Guideline Update
The use of acetyl-L-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Slides, a recommendations table, interventions table, patient information, including a patient-focused podcast, and a visual abstract are available.